DC HEALTHCARE HOLDINGS BERHAD

Registration No. 202201014036 (1459733-P)
(Incorporated in Malaysia)

INTERIM FINANCIAL REPORT
FOR THE FIRST QUARTER ENDED
31 MARCH 2026

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE FIRST QUARTER ENDED 31 MARCH 2026

	Note	3-MONTH ENDED 31.03.2026 RM'000	3-MONTH ENDED 31.03.2025 RM'000	PERIOD TO DATE 31.03.2026 RM'000	PERIOD TO DATE 31.03.2025 RM'000
Revenue	A9	21,363	17,903	21,363	17,903
Cost of sales		(11,179)	(8,781)	(11,179)	(8,781)
Gross profit		10,184	9,122	10,184	9,122
Other income		136	148	136	148
Staff costs		(2,030)	(2,325)	(2,030)	(2,325)
Administrative expenses		(7,438)	(7,370)	(7,438)	(7,370)
Profit / (Loss) from Operations		852	(425)	852	(425)
Interest expense		(529)	(414)	(529)	(414)
Profit / (Loss) before tax	B12	323	(839)	323	(839)
Taxation	B6	(205)	-	(205)	-
Profit / (Loss) after tax		118	(839)	118	(839)
Profit / (Loss) for the financial period, representing total comprehensive income for the financial period		118	(839)	118	(839)
Profit / (Loss) for the financial period attributable to:					
Owners of the Company		118	(839)	118	(839)
		118	(839)	118	(839)
Total comprehensive Profit / (Loss) for the financial period attributable to:					
Owners of the Company		118	(839)	118	(839)
		118	(839)	118	(839)
Earning / (Loss) per share attributable to Owners of the Company:					
Basic (sen) [1]	B11	0.01	(0.08)	0.01	(0.08)
Diluted (sen) [1]	B11	0.01	(0.08)	0.01	(0.08)
Enlarged share capital		996,300,000		996,300,000	

Note:

(1) The basic and diluted earnings per share ("**EPS**") / loss per share ("**LPS**") are calculated based on the weighted average number of ordinary shares referred to in Note B11.

The Unaudited Consolidated Statement of Profit or Loss and Other Comprehensive Income should be read in conjunction with the Audited Financial Statements for the financial year ended 31 December 2025 and the accompanying explanatory notes attached to the consolidated interim financial report.

UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 31 MARCH 2026

	UNAUDITED AS AT 31.03.2026 RM'000	AUDITED AS AT 31.12.2025 RM'000
ASSETS		
Non-current assets		
Plant and equipment	43,022	44,605
Right-of-use assets	29,395	32,686
Other Investment	1,722	1,722
Deferred tax assets	1,542	1,542
Other Receivables	250	250
Total non-current assets	**75,931**	**80,805**
Current assets		
Inventories	3,365	3,651
Trade receivables	217	200
Other receivables, deposits and prepayments	6,773	5,940
Short-term funds	15,194	15,072
Fixed deposits with licensed banks	1,777	1,702
Cash and cash equivalents	7,660	8,212
Total current assets	**34,986**	**34,777**
TOTAL ASSETS	**110,917**	**115,582**
EQUITY AND LIABILITIES		
Equity		
Share capital	57,428	57,428
Accumulated losses	(3,604)	(3,722)
Reorganization reserves	(8,764)	(8,764)
TOTAL EQUITY	**45,060**	**44,942**
Liabilities		
Non-current liabilities		
Lease liabilities	22,111	25,746
Borrowings	9,075	8,895
Provision	146	258
Total non-current liabilities	**31,332**	**34,899**
Current liabilities		
Trade payables	2,374	1,731
Other payables and accruals	5,898	6,725
Contract liabilities	15,839	17,198
Lease liabilities	7,805	7,364
Borrowings	2,418	2,410
Tax Payable	191	313
Total current liabilities	**34,525**	**35,741**
TOTAL LIABILITIES	**65,857**	**70,640**
TOTAL EQUITY AND LIABILITIES	**110,917**	**115,582**

UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 31 MARCH 2026 (CONT'D)

	UNAUDITED AS AT 31.03.2026	AUDITED AS AT 31.12.2025
Weighted average number of ordinary shares ('000)	996,300	996,300
Net assets per share (RM)	0.05	0.05

The Unaudited Consolidated Statement of Financial Position should be read in conjunction with the Audited Financial Statements for the financial year ended 31 December 2025 and the accompanying explanatory notes attached to the consolidated interim financial report.

THE REST OF THIS PAGE HAS BEEN INTENTIONALLY LEFT BLANK

UNAUDITED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE FIRST QUARTER ENDED 31 MARCH 2026

	Share Capital RM'000	Reorganisation Reserves RM'000	Accumulated Losses RM'000	Total Equity RM'000
Unaudited				
As at 1 January 2026	57,428	(8,764)	(3,722)	44,942
Profit net of tax, representing total comprehensive income for the financial period	-	-	118	118
As at 31 March 2026	57,428	(8,764)	(3,604)	45,060

	Share Capital RM'000	Reorganisation Reserves RM'000	Accumulated Losses RM'000	Total Equity RM'000
Audited				
As at 1 January 2025	57,428	(8,764)	(3,928)	44,736
Profit net of tax, representing total comprehensive income for the financial period	-	-	206	206
As at 31 December 2025	57,428	(8,764)	(3,722)	44,942

The Unaudited Consolidated Statement of Changes in Equity should be read in conjunction with the Audited Financial Statements for the financial year ended 31 December 2025 and the accompanying explanatory notes attached to the consolidated interim financial report.

UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE FIRST QUARTER ENDED 31 MARCH 2026

	PERIOD TO DATE	
	31.03.2026	31.03.2025
	RM'000	RM'000
Cash Flows From Operating Activities		
Profit / (Loss) before tax	323	(839)
Adjustments for:		
Depreciation of plant and equipment	1,569	1,585
Depreciation of right-of-use assets	1,788	1,893
Interest expense	529	414
Interest income	(122)	(148)
Operating profit before working capital changes	4,087	2,905
Changes In working capital:		
Inventories	286	167
Contract liabilities	(1,359)	978
Receivables	(850)	(1,420)
Payables	(180)	(1,044)
Cash generated from operations	1,984	1,586
Interest paid	(529)	(414)
Interest received	122	148
Income tax paid	(327)	(80)
Net cash from operating activities	1,250	1,240
Cash Flows From Investing Activities		
Purchase of plant and equipment	(1,263)	(1,519)
Additional of right-of-use assets	2,663	2,567
Net cash from investing activities	1,400	1,048
Cash Flows From Financing Activities		
Net repayment of lease liabilities	(3,194)	(1,857)
Net drawdown of loans	189	457
Net cash used in financing activities	(3,005)	(1,400)
Net increase / (decrease) in cash and cash equivalents	(355)	888
Cash and cash equivalents at the beginning of the financial period	24,986	26,216
Cash and cash equivalents at the end of the financial period	24,631	27,104

UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE FIRST QUARTER ENDED 31 MARCH 2026 (CONT'D)

	PERIOD TO DATE	
	31.03.2026	**31.03.2025**
	RM'000	**RM'000**
CASH AND BANK BALANCES		
Cash on hand and at banks	22,854	25,629
Deposits placed with licensed banks	1,777	1,475
	24,631	27,104
Less: Non-short term deposit placed with licensed bank	-	-
Cash and bank balances	24,631	27,104

The Unaudited Consolidated Statement of Cash Flows should be read in conjunction with the Audited Financial Statements for the financial year ended 31 December 2025 and the accompanying explanatory notes attached to the consolidated interim financial report.

THE REST OF THIS PAGE HAS BEEN INTENTIONALLY LEFT BLANK

A. NOTES TO THE INTERIM FINANCIAL REPORT

A1. Basis of preparation

The interim financial report of DC Healthcare and its subsidiaries ("**Group**") is unaudited and has been prepared in accordance with the requirements of Malaysian Financial Reporting Standards ("**MFRS**") No. 134: Interim Financial Reporting and Rule 9.22 and Appendix 9B of the ACE Market Listing Requirements of Bursa Malaysia Securities Berhad ("**Listing Requirements**").

This interim financial report should be read in conjunction with the Audited Financial Statements for the financial year ended 31 December 2025 as disclosed in the Annual Report 2025 and the accompanying explanatory notes attached to the consolidated interim financial report.

A2. Summary of significant accounting policies

The accounting policies and methods of computation adopted by the Group in this interim financial report are consistent with those adopted as disclosed in the Accountants' Report in the Prospectus, except for the adoption of the following MFRSs, Amendments to MFRSs and new Interpretations effective for the financial periods beginning on or after 1 January 2025.

Standards issued but not yet effective

	Effective dates for financial periods beginning on or after
● Amendments to MFRS 9 and MFRS 7 *Classification and Measurement of Financial Instruments*	1 January 2026
Amendments that are part of Annual Improvement – Volume 11:	
● Amendments to MFRS 1 *First-time Adoption of Malaysian Financial Reporting Standards*	1 January 2026
● Amendments to MFRS 7 *Financial Instruments: Disclosures*	1 January 2026
● Amendments to MFRS 9 *Financial Instruments*	1 January 2026
● Amendments to MFRS 10 *Consolidated Financial Statements*	1 January 2026
● Amendments to MFRS 107 *Statements of Cash Flows*	1 January 2026
● Amendments to MFRS 9 and MFRS 7 *Contract Referencing Nature-dependent Electricity*	1 January 2026
● MFRS 18 *Presentation and Disclosure in Financial Statements*	1 January 2027
● MFRS 19 *Subsidiaries without Public Accountability Disclosures*	1 January 2027
● Amendments to MFRS 121 *The Effects of Changes in Foreign Exchange rates*	1 January 2027

A. NOTES TO THE INTERIM FINANCIAL REPORT (CONT'D)

A2. Summary of significant accounting policies (Cont'd)

	Effective dates for financial periods beginning on or after
• Amendments to MFRS 10 and MFRS 128 *Sales or Contribution of Assets between an Investor and its Associate or Joint Venture*	To be announced

The Group will adopt the above accounting pronouncements when they become effective in the respective financial periods. These accounting pronouncements are not expected to have any effect to the financial statements of the Group upon their initial applications.

A3. Auditors' report on preceding annual financial statements

There was no qualification on the audited consolidated financial statements of the Group for the financial year ended 31 December 2025.

A4. Seasonal or cyclical factors

The business operations of the Group were not materially affected by any seasonal and cyclical effects during the current financial quarter and financial period-to-date.

A5. Unusual items affecting assets, liabilities, equity, net income or cash flows

There were no unusual items affecting assets, liabilities, equity, net income or cash flows of the Group during the current financial quarter and financial period-to-date.

A6. Material changes in estimates

There were no material changes in the estimates that have a material effect to the Group in the current financial quarter and financial period-to-date.

A7. Debt and equity securities

There were no issuances, cancellations, repurchases, resale and repayment of debts and equity during the current financial quarter under review.

A8. Dividends paid

There was no dividend paid during the current financial quarter under review.

THE REST OF THIS PAGE HAS BEEN INTENTIONALLY LEFT BLANK

A. NOTES TO THE INTERIM FINANCIAL REPORT (CONT'D)

A9. Segmental information

The Group's segmental information as follows:

	3-MONTH ENDED		PERIOD TO DATE	
	31.03.2026 RM'000	31.03.2025 RM'000	31.03.2026 RM'000	31.03.2025 RM'000
Aesthetic services	18,683	14,859	18,683	14,859
General medical services	1,881	2,327	1,881	2,327
Sale of skincare products	799	717	799	717
Total	21,363	17,903	21,363	17,903
Segment profit	10,184	9,122	10,184	9,122
Other income	136	148	136	148
Staff costs	(2,030)	(2,325)	(2,030)	(2,325)
Administrative expenses	(7,438)	(7,370)	(7,438)	(7,370)
Finance costs	(529)	(414)	(529)	(414)
Taxation	(205)	-	(205)	-
Profit / (Loss) for the financial period	118	(839)	118	(839)

A10. Valuation of property, plant and equipment

There was no valuation of the property, plant and equipment in the current financial quarter under review.

A11. Material events subsequent to the end of the current financial quarter

There were no other material events subsequent to the end of the current financial quarter that have not been reflected in this interim financial report.

A12. Changes in the composition of the Group

Saved as disclosed below, there were no material changes in the composition of the Group for the current financial quarter under review.

The Company had on 30 January 2026 incorporated a new subsidiary known as DC Pinnacle Sdn Bhd ("**DCPN**"), which has an issued share capital of RM1,000.00, comprising 1,000 ordinary shares. The shareholders of DCPN are DC Healthcare (65.00%) and Marvest Elite Holding Sdn Bhd (35.00%).

The principal activities of DCPN are provision of aesthetic and general medical services and sale of general skincare products. The subsidiary is currently dormant as at first quarter ended 31 March 2026.

A. NOTES TO THE INTERIM FINANCIAL REPORT (CONT'D)

A13. Contingent assets and contingent liabilities

There were no contingent assets and contingent liabilities as at the date of this interim report.

A14. Material capital commitments

There is no material commitment for capital expenditure, which upon becoming enforceable, may have a material effect on the Group's financial position as at the date of this interim financial report.

A15. Significant related party transactions

There were no significant related party transactions during the current financial quarter under review.

THE REST OF THIS PAGE HAS BEEN INTENTIONALLY LEFT BLANK

B. EXPLANATORY NOTES PURSUANT TO APPENDIX 9B OF THE LISTING REQUIREMENTS

B1. Review of performance

Results for current quarter

	3-MONTH ENDED			
	31.03.2026	**31.03.2025**	**Changes**	
	RM'000	**RM'000**	**RM'000**	%
Revenue	21,363	17,903	3,460	19%
Profit / (Loss) before tax	323	(839)	1,162	138%

The Group recorded a revenue of RM21.36 million for the current financial quarter ended 31 March 2026 which represented an increase of RM3.46 million or 19% as compared to RM17.90 million for the preceding year corresponding quarter ended 31 March 2025.

The Group's revenue was principally derived from the aesthetic segment, which contributed RM18.68 million or 87% of the total revenue for the current financial quarter ended 31 March 2026. This represented an increase in revenue from the aesthetic segment of RM3.82 million or 26% as compared to RM14.86 million for the preceding year corresponding quarter ended 31 March 2025. The growth was mainly due to increase in the Group's cash sales collection and higher redemption of aesthetic services during the current financial quarter. The higher revenue also translated into a higher gross profit of RM10.18 million in the current financial quarter from RM9.12 million in the preceding year corresponding quarter ended 31 March 2025.

The Group recorded a profit before tax of RM0.32 million for the current financial quarter ended 31 March 2026, compared to loss before tax of RM0.84 million for the preceding year corresponding quarter ended 31 March 2025. The improvement was primarily due to the higher gross profit coupled with lower staff costs incurred during the current financial quarter under review.

THE REST OF THIS PAGE HAS BEEN INTENTIONALLY LEFT BLANK

B. EXPLANATORY NOTES PURSUANT TO APPENDIX 9B OF THE LISTING REQUIREMENTS (CONT'D)

B2. Comparison with immediate preceding quarter's results

	3-MONTH ENDED			
	Current Quarter 31.03.2026 RM'000	**Preceding Quarter 31.12.2025 RM'000**	**Changes RM'000**	**%**
Revenue	21,363	21,909	(546)	-2%
Profit before tax	323	473	(150)	-32%

The Group's revenue for the current financial quarter ended 31 March 2026 reduced by RM0.55 million or 2% to RM21.36 million as compared to the immediately preceding quarter 31 December 2025 of RM21.91 million. The decrease in revenue was mainly due to lower redemption rate in aesthetic services.

The Group's profit before tax for the current financial quarter ended 31 March 2026 reduced by RM0.15 million or 32% to RM0.32 million as compared to profit before tax of RM0.47 million in the immediately preceding financial quarter ended 31 December 2025. The decrease in profit before tax was due to decrease in other income in the current financial quarter as compared to preceding quarter.

THE REST OF THIS PAGE HAS BEEN INTENTIONALLY LEFT BLANK

B. EXPLANATORY NOTES PURSUANT TO APPENDIX 9B OF THE LISTING REQUIREMENTS (CONT'D)

B3. Prospects

The Group remains focused on strengthening its market position within the medical aesthetic and wellness industry through continuous enhancement of its service offerings, operational capabilities, and customer engagement strategies. Efforts continue to be directed towards reinforcing the Group's core business, while broadening its range of skincare and wellness products to cater to evolving consumer preferences and market demand.

In line with the Group's commitment to improving customer experience and treatment outcomes, the Group continues to explore digitalisation initiatives and technology-driven solutions to support service personalisation and operational efficiency. This includes the gradual integration of Artificial Intelligence-assisted skin analysis tools and data-driven consultation approaches aimed at enhancing patient engagement and service quality.

Operationally, the Group is undertaking ongoing initiatives to improve productivity, optimise resource utilisation, and strengthen cost management across its clinic network and corporate functions. The implementation of the enterprise resource planning ("ERP") system remains a key initiative to support process integration, improve operational visibility, and facilitate more efficient decision-making across the organisation.

These strategic initiatives are designed to drive sustainable growth, enhance operational excellence, and ensure financial stability, reinforcing the Group's leadership in the medical aesthetic and wellness industry.

B4. Profit forecast or profit guarantee

The Group did not issue any profit forecast or profit guarantee during the current financial quarter under review.

B5. Status of corporate proposals

There were no corporate proposals announced but not completed as at the date of this interim report.

THE REST OF THIS PAGE HAS BEEN INTENTIONALLY LEFT BLANK

B. EXPLANATORY NOTES PURSUANT TO APPENDIX 9B OF THE LISTING REQUIREMENTS (CONT'D)

B6. Income tax expense

	3-MONTH ENDED		PERIOD TO DATE	
	31.03.2026 RM'000	31.03.2025 RM'000	31.03.2026 RM'000	31.03.2025 RM'000
Income tax:				
- Under / (Overprovision) for prior year	-	-		-
- Current year	205	-	205	-
	205		205	-
Total Taxation	205	-	205	-
Effective tax rate (%)	63.47	0.00	63.47	0.00

The effective tax rate was higher than the statutory tax rate of 24% for the current quarter and period-to-date mainly due to recognition of estimated tax instalments for current year.

B7. Bank borrowings

The Group's bank borrowings were as follows:

	UNAUDITED 31.03.2026 RM'000	AUDITED 31.12.2025 RM'000
Current		
Term loan	1,891	2,259
Overdraft	527	151
	2,418	2,410
Non Current		
Term loan	9,075	8,895
	9,075	8,895
Total	11,493	11,305

All the Group's bank borrowings are denominated in Ringgit Malaysia.

B8. Deferred Tax

	UNAUDITED 31.03.2026 RM'000	AUDITED 31.12.2025 RM'000
Opening	1,542	1,495
Recognised in profit or loss	-	47
Total deferred tax assets	1,542	1,542

B. EXPLANATORY NOTES PURSUANT TO APPENDIX 9B OF THE LISTING REQUIREMENTS (CONT'D)

B9. Material litigation

There was no material litigation involving the Group as at 31 March 2026.

B10. Dividend

No dividend has been declared or proposed for the current financial quarter under review.

B11. EPS / (LPS)

The basic and diluted EPS / (LPS) are computed as follows:

	3-MONTH ENDED		PERIOD TO DATE	
	31.03.2026 RM'000	31.03.2025 RM'000	31.03.2026 RM'000	31.03.2025 RM'000
Basic EPS / (LPS) (sen)				
Profit / (Loss) after tax attributable to Owners of the Company (RM'000)	118	(839)	118	(839)
Number of ordinary shares ('000)	996,300	996,300	996,300	996,300
Basic EPS / (LPS) (sen)	0.01	(0.08)	0.01	(0.08)
Diluted EPS / (LPS) (sen)				
Profit / (Loss) after tax attributable to Owners of the Company (RM'000)	118	(839)	118	(839)
Number of ordinary shares ('000)	996,300	996,300	996,300	996,300
Effects of dilutive potential ordinary shares from ESOS('000)	-	-	-	-
Diluted EPS / (LPS) (sen)	0.01	(0.08)	0.01	(0.08)

B12. Disclosure on selected expense/income items as required by the Listing Requirements

Profit / Loss before tax has been arrived at after charging/(crediting):

	3-MONTH ENDED		PERIOD TO DATE	
	31.03.2026 RM'000	31.03.2025 RM'000	31.03.2026 RM'000	31.03.2025 RM'000
Depreciation of plant and equipment	1,569	1,585	1,569	1,585
Depreciation of right-of-use assets	1,788	1,893	1,788	1,893
Interest expense	529	414	529	414
Interest income	(122)	(148)	(122)	(148)

Other disclosure items pursuant to Appendix 9B, Note 16 of the Listing Requirements are not applicable.

THE REST OF THIS PAGE HAS BEEN INTENTIONALLY LEFT BLANK

B. EXPLANATORY NOTES PURSUANT TO APPENDIX 9B OF THE LISTING REQUIREMENTS (CONT'D)

B13. Comparative Figures

Comparative figures, where applicable, have been modified to conform with the current quarter presentation.

B14. Approval of Interim Financial Report

The interim financial report as set out above was approved by the Board of Directors in accordance with a resolution dated 25 May 2026.

THE REST OF THIS PAGE HAS BEEN INTENTIONALLY LEFT BLANK